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Abstract: As a result of the continuous evolution of microbial pathogens towards 
antibiotic-resistance, there have been demands for the development of new and effective 
antimicrobial compounds. Since the 1960s, the scientific literature has accumulated many 
publications about novel pharmaceutical compounds produced by a diverse range of marine 
bacteria. Indeed, marine micro-organisms continue to be a productive and successful focus 
for natural products research, with many newly isolated compounds possessing potentially 
valuable pharmacological activities. In this regard, the marine environment will 
undoubtedly prove to be an increasingly important source of novel antimicrobial 
metabolites, and selective or targeted approaches are already enabling the recovery of a 
significant number of antibiotic-producing micro-organisms. The aim of this review is to 
consider advances made in the discovery of new secondary metabolites derived from 
marine bacteria, and in particular those effective against the so called “superbugs”, 
including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant 
enterococci (VRE), which are largely responsible for the increase in numbers of hospital 
acquired, i.e., nosocomial, infections. 
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1. Introduction 
 
The search for new antibiotics is an important element in the fight against the threat posed by the 
increase in the number of infections caused by antibiotic-resistant pathogens. Literature reviews show 
that most antibiotics used today originate from a small set of scaffold compounds, with many other 
antibiotics being synthetically derived from them [1]. Resistance of pathogenic bacteria toward 
antibiotics is certainly increasing, but the rate of discovery and development of new and effective 
antibiotic compounds is declining [2,3]. Among the clinically used antibiotics, over two thirds have 
been discovered from natural sources or are the semi-synthetic derivatives of natural antibiotics [4]. 
Until now, the dominant effort to discover new antibiotics has involved the terrestrial environment 
whereas, in comparison, little attention has been given to marine microbial metabolites. Indeed, by the 
end of 2008, only ~3000 microbial metabolites had been reported from marine sources, which is far 
less than the number of compounds isolated from other natural sources [5,6]. A long-held belief of 
many scientists that seawater contained few microbes was the main reason for overlooking the 
secondary metabolites from marine micro-organisms. Pentabromopseudilin [7] (Figure 1), which was 
the first marine antibiotic to be recognized, was discovered in 1966. Yet, the majority of natural 
antibiotics have been found in soil-borne actinomycetes, perhaps because they can be readily and 
easily recovered and cultured, as well as the perception that they dominate as antibiotic-producers. The 
marine environment with its diverse microflora is likely to be a very promising source of novel 
antibiotic producers. Indeed, a new anti-folate scaffold, termed abyssomicin, was recently isolated 
from a marine Verrucosispora, which is a rare actinomycete genus belonging to the family 
Micromonosporaceae [8]. Thus, it is reasoned that marine microbial metabolites offer the prospect of 
potential candidates for new drug discovery programmes [9]. Indeed, there are already some detailed 
reviews on marine natural products [10,11] with some focusing on compounds for infectious diseases, 
examples of which include products with antituberculosis [12], antiviral [13], antiparasitic [14], 
antinematodal [15] and antifungal [16] activity. Consequently, the main objective of this article is to 
highlight the importance of marine bacteria as a potential source of new compounds with activity 
against hospital-acquired infectious diseases, especially methicillin resistant Staphylococcus aureus 
(MRSA) and vancomycin resistant enterococci (VRE). 
Figure 1. Structure of pentabromopseudilin. 
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2. Anti-methicillin-resistant Staphylococcus aureus (MRSA) and Anti-vancomycin-resistant 
Enterococci (VRE) Compounds Derived from Marine Bacteria 
 
MRSA infection is considered to be one of the main causes of death among the hospital-acquired 
infectious diseases, and has led to many thousands of deaths and additional expenditure estimated as 
3–4 billion dollars for health care in the USA [17]. MRSA is a Gram-positive spherical organism, 
often occurring as clusters of cells. The organism can rapidly mutate to acquire resistance to 
antibacterial agents [18,19] and is highly resistant to commercially available antibiotics, with the 
exception of teicoplanin (Figure 2) and vancomycin (Figure 3) [20,21]. Worryingly, recent studies 
have identified the existence of vancomycin-resistant [22,23] and teicoplanin-resistant S. aureus 
[24,25]. Thus, there is urgency for the development of new drugs effective against MRSA. The first 
report of vancomycin resistance was published in 1988, and described an isolate of Enterococcus 
faecium [26]. Unfortunately, the number of vancomycin-resistant isolates of S. aureus or Enterococcus 
(VRSA and VRE) causing disease is steadily increasing, but they are as yet less prevalent than MRSA 
[27]. However, treatment of VRE is more difficult as there are no effective alternative antibiotics  
available [28]. 
 
Figure 2. Structure of teicoplanin. 
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Figure 3. Structure of vancomycin. 
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Cultivation of a marine Streptomyces sp. (CNQ-418) recently yielded two densely halogenated 
metabolites, marinopyrroles A and B (Figure 4), which showed potent activity against MRSA 
[minimum inhibitory concentrations (MIC) ≤ 2 μM] as well as cytotoxicity against a human cancer cell 
line (HCT-116) [29]. Like pentabromopseudilin, marinopyrroles A and B possess halogenated pyrrole 
subunits, although the N,C2-linked bispyrrole motif that they embody has not previously been observed 
in natural product construction, and they constitute a structurally novel class of antibiotic. Notably the 
biaryl bond in these compounds, flanked by four ortho substituents, establishes an axis of chirality, and 
the fact that both structures were isolated as single (–)-atropo-enantiomers may suggest a key  
enzyme-mediated pyrrole coupling in their biosynthesis. Studies with marinopyrrole A showed that the 
biaryl linkage is configurationally stable at room temperature, although the compound can be 
racemized at elevated temperatures to yield the non-natural (+)-enantiomer. Interestingly, the latter had 
comparable activity against MRSA [MIC 0.31 µM versus 0.61 µM for the (–)-enantiomer]. However, 
the mechanism of action of these compounds has yet to be defined. 
 
Figure 4. Structure of marinopyrroles A and B. 
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Figure 5. Structure of thiomarinols A-G and pseudomonic acids A and C. 
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Another marine bacterium, Alteromonas rava SANK 73390, has been shown to produce several 
sulphur-containing secondary metabolites, thiomarinols A-G (Figure 5a–g), with broad spectrum 
activity against Gram-positive and Gram-negative species [30–33]. The thiomarinols are especially 
active against Gram-positive bacteria and have pronounced activity against MRSA, in particular  
(MICs ≤ 0.01 µg/mL). Their antibacterial mode of action is reportedly mediated by inhibition of 
bacterial isoleucyl-transfer RNA synthetase, the same mechanism as described [34] for the structurally 
related pseudomonic acids (e.g., pseudomonic acids A and C, Figure 5h/5i), which were originally 
isolated from Pseudomonas fluorescens NCIMB 10586 [35] and are the main constituents in the 
topical antibiotic, mupirocin. Studies with thiomarinols A, B and D revealed pronounced specificity 
for inhibition of isoleucyl-tRNA synthetase over the valyl- and leucyl-tRNA synthetases [30]. 
Two halogenated biphenyl secondary metabolites, MC21-A (Figure 6) and MC21-B (Figure 7), 
were isolated from the marine bacterium Pseudoalteromonas phenolica O-BC30T, and demonstrated 
activity against ten clinical isolates of MRSA with MICs of 1–4 µg/mL [36]. Significantly the level of 
activity of these compounds was comparable to that of vancomycin (MICs of 0.25–2 µg/mL). MC21-A 
had no cytotoxic effect on human normal fibroblasts, and exhibited significant bactericidal activity, 
which was also comparable with that of vancomycin. In contrast, MC21-B (Figure 7) was found to be 
cytotoxic to human normal dermal fibroblasts and human leukaemia cells [37]. Subsequent studies 
determined that MC21-A killed MRSA cells by interfering with the permeability of the cell  
membrane [38]. MC21-A also showed high activity against Enterococcus seriolicida, Enterococcus 
faecium, and Enterococcus faecalis.  
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Figure 6. Structure of MC21-A. 
OH
OH
Br
Br
Br
Br
 
Figure 7. Structure of MC21-B. 
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Actinomycetes isolated from samples of Korean marine silt have also been screened for production 
of anti-MRSA natural products. During this work a compound (AM3) with potent anti-MRSA activity 
was isolated from the culture broth of a Streptomyces strain, AM045 [39]. The level of activity 
exhibited by the compound (MIC: 0.1~0.4 µg/mL) was higher than that of vancomycin or teicoplanin, 
but the structure was subsequently identified as actinomycin V (Figure 8) [39]. 
 
Figure 8. Structure of actinomycin V. 
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Culture extracts from two hundred marine and terrestrial actinomycetes were recently screened in a 
search for novel antibacterial compounds that specifically disrupt biosynthesis of para-aminobenzoic 
acid (pABA), a key intermediate en route to tetrahydrofolate. These screens led to the discovery of 
abyssomicin C (Figure 9a), a complex polyketide-type compound isolated from a marine strain, 
Verrucosispora AB-18-032, which was obtained from a sediment sample collected in the Sea of Japan 
at a depth of 289 m [40,41]. Abyssomicin C showed good inhibitory activity against MRSA and 
VRSA (MIC 4–13 µg/mL), though two analogues (abyssomicins B and D, Figure 9b/c), which were 
isolated at the same time, lacked any antibacterial activity. The activity of abyssomicin C, the first 
natural compound reported to inhibit biosynthesis of pABA, prompted attempts to develop synthetic 
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routes to the compound and these culminated in successful total syntheses [42–44]. Remarkably, 
conformational constraints in the macrocyclic ring led to the issue of two isolable atropisomeric states 
from the total synthesis undertaken by Nicolaou’s group [42], abyssomicin C and atrop-abyssomicin C 
(Figure 9a and 9d respectively); the latter isomer was somewhat more potent in its activity against 
MRSA. Although initially thought to be a non-natural isomer, atrop-abyssomicin C was subsequently 
also recovered from cultures Verrucosispora AB-18-032 together with a further two analogues, 
abyssomicins G and H (Figure 9e and 9f), that lacked antibacterial activity [40]. One other member of 
this natural product family, abyssomicin E (Figure 9g), has also been isolated but from a terrestrial 
Streptomyces sp. (HKI0381) [45]. Also, this compound did not exhibit antibacterial activity. The 
antibacterial activity of abyssomicin C and its atropisomer is therefore strongly dependent on the 
presence of the Michael acceptor unit within the macrocyclic ring, and the absence of this feature in 
abyssomicins B, D, E, G and H accounts for their lack of activity. The importance of the Michael 
acceptor unit is further underlined by the finding that reduction of the enone carbonyl in abyssomicin 
C ablates activity [46]. Blockade of pABA biosynthesis by abyssomicin C arises from inhibition of 
enzymes that process chorismate [41,47], and it has been noted [41] that the abyssomicin 
oxabicycloctane system bears a striking resemblance to known transition-state analogue inhibitors of 
chorismate mutase (Figure 9h) [48]. 
 
Figure 9. Structure of abyssomicins. 
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Culture extracts of another marine actinomycete, Streptomyces platensis (TP-A0598), yielded four 
secondary metabolites, TPU-0037-A to D (Figure 10b–e), that exhibited activity against MRSA with 
MICs in the range 3–13 µg/mL [49]. These compounds are close congeners of an established 
antibiotic, lydicamycin (Figure 10a), that was originally isolated from cultures of Streptomyces lydicus 
taken from a soil sample [50,51]. Lydicamycin exhibited anti-MRSA activity with a MIC of  
6 µg/mL [49]. 
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Figure 10. Structure of lydicamycin and TPU-0037-A to D. 
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Figure 11. Structure of bisanthraquinones BE-43472A to D. 
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Four unusual, streptomycete-derived bisanthraquinone compounds with antitumor-antibiotic 
activity, BE-43472A to D (Figure 11a-d), were first claimed in a Japanese patent in 1996 [52]. A 
decade later, the compounds were also reported as natural products from a marine Streptomyces strain 
(N1-78-1) isolated from cultured cells of an unidentified cyanobacterium (URI strain N36-11-10), 
itself collected from a Puerto Rican ascidian, Ecteinascidia turbinata [53,54]. In this latter study, the 
relative stereochemistry of the compounds was defined and the compounds were determined to have 
potent antibacterial activity against MRSA and VRE, as well as cytotoxic activity against HCT-116 
cells. BE-43472B exhibited the most potent activity against MRSA and VRE with MICs in the range 
0.11–0.45 µM, and a minimum bactericidal concentration against a number of clinical MRSA isolates 
in the range 0.91–3.6 µM; 29 µM against VRE [54]. In the initial reports [53,54] the structures of  
BE-43472A to D were depicted with antipodal stereochemistry to that shown in Figure 11. 
Unambiguous assignment of the absolute stereochemistry was subsequently facilitated, however, with 
the successful total synthesis of both enantiomers of BE-43472B [55,56]. Interestingly the unnatural  
(–)-BE-43472B enantiomer was found to exhibit comparable antibacterial activity to that of the natural 
(+)-enantiomer (Figure 11b). 
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A number of structurally less complex natural products with activity against MRSA and VRE have 
also been isolated from cultures of marine bacteria since 2000. Thus, a new class of 2-alkylidene-4-
oxazolidinone, exhibiting an unprecedented antibiotic pharmacophore, was isolated from a marine 
actinomycete (NPS8920) [57,58]. A series of three compounds in this class, lipoxazolidinones A to C 
(Figure 12), was isolated, with the most potent activity against MRSA and VRE exhibited by congener 
A (MICs: 1–2 µg/mL). Absolute stereochemistry for the lipoxazolidinones has yet to be determined. 
The ubiquitous bacterial type II fatty acid synthase (FASII) is essential for bacterial viability. A 
screening programme designed to discover new antibiotics that block bacterial fatty acid biosynthesis 
by targeting the FASII complex recently identified two lipophilic α-pyrones from a marine 
Pseudomonas sp. (F92S91) (Figure 13) that possessed activity against MRSA, VRE and other bacteria 
[59]. Pyrone I (Figure 13a) was the more potent of the two compounds, exhibiting MICs in the range 
of 2–4 µg/mL and 2–64 µg/mL against MRSA and VRE strains, respectively. Investigations with 
Bacillus subtilis showed that pyrone I interferes with membrane function and non-specifically inhibits 
incorporation of radio-labeled precursors into RNA, DNA and protein. Another marine Pseudomonas 
sp. (strain AMSN), which was isolated from the surface of a red alga (Ceratodiction spongiosum), 
produced 2,4-diacetylphloroglucinol (DAPG; Figure 14) which exhibited potent anti-MRSA,  
anti-VRSA and anti-VRE activities against a panel of clinical isolates with MICs in the range  
1–8 µg/mL [60–62]. This simple, robust compound, which is stable at temperatures up to 70 °C and 
across a wide pH range (pH 2–7), lacked acute toxicity in mice at levels of up to 100 mg/kg. The 
inhibition of cellular lipid biosynthesis is thought to underpin the antibacterial activity of another 
polyphenolic antibiotic, platensimycin (Figure 15), disclosed by Merck in 2006 [63]. The Merck group 
isolated platensimycin from cultures of Streptomyces platensis, recovered from soil samples, although 
the compound had previously been isolated from marine bacteria in work that was unpublished [64]. 
Platensimycin demonstrated broad spectrum activity against Gram-positive bacteria and was very 
effective against antibiotic-resistant strains, including MRSA, vancomycin-intermediate-resistant S. 
aureus (VISA) and VRE, successfully eradicating MRSA infection in mice. Platensimycin reportedly 
inhibits the elongation condensing enzymes, FabF/B, that are essential components of fatty-acid 
biosynthesis in FASII and are highly conserved in pathogens [63]. A recent report, however, calls into 
question the attractiveness of FASII as target pathway for development of next generation  
antibiotics [65]. 
 
Figure 12. Lipoxazolidinones A to C. 
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Figure 13. Pyrones I and II. 
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Figure 14. 2,4-Diacetylphloroglucinol. 
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Figure 15. Platensimycin. 
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Peptides also feature among the naturally occurring compounds from marine bacteria that possess 
activity against antibiotic-resistant pathogens (Figure 16). Thus, a novel peptide antibiotic, bogorol A 
(Figure 16a), which was isolated from a marine Bacillus, was found to possess good activity against 
MRSA and VRE (MICs of 2 µg/mL and 10 µg/mL respectively) [66]. Bogorol A exhibited more 
modest activity against Escherichia coli (35 µg/mL), Burkholderia cepacia (200 µg/mL), 
Pseudomonas aeruginosa (200 µg/mL) and Candida albicans (200 µg/mL). Significant features of the 
structure include unusual terminal subunits, as the structure contains both a reduced C-terminal valine 
modification and an N-terminal (R)-hydroxy acid subunit. Chiral HPLC analysis of the derivatised 
hydrolysate of bogorol A was used to determine the stereochemistry of constituent amino acids. As the 
compound was found to possess both L- and D-leucine as well as L- and D-lysine, assignment of 
absolute configuration to all of the stereogenic centres in the structure was not possible. However, 
bogorol A may provide a basis for a combinatorial approach to new agents with activity against MRSA 
and VRE. Four cyclic decapeptide antibiotics, loloatins A to D (Figure 16b), were isolated from 
another marine Bacillus sp. MK-PNG-276A, which was collected from the Great Barrier Reef off 
Papua New Guinea [67–69]. Loloatins A-D exhibited in vitro antimicrobial activity against MRSA 
(MICs respectively: 4 µg/mL, 2 µg/mL, 0.5 µg/mL and 8µg/mL) as well as VRE (MICs: 4 µg/mL,  
2 µg/mL, 1 µg/mL and 8 µg/mL). A number of reports have subsequently discussed the solution phase 
conformation of the loloatins and described the synthesis of loloatin anlogues [70–74]. 
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Figure 16. Peptidic antibiotics derived from marine bacteria. 
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Figure 17. Structure of marinomycins. 
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A series of bioactive polyene-polyols, marinomycins A to D (Figure 17), was isolated from a newly 
discovered marine actinomycete genus named Marinispora [75]. Congeners A, B and D were found to 
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possess a symmetrical macrodiolide construction, whereas marinomycin C was unsymmetrical. 
Marinomycin A exhibited the most potent antibacterial activity of the series, with an in vitro MIC of 
0.13 μM against both MRSA and VRE; marinomycins B to D were active against MRSA  
(MIC ~0.25 μM in each case) but these three congeners showed no significant activity against VRE. 
The structure of marinomycin A is reminiscent of other well-known polyene antifungal-antibiotics, 
such as amphotericin B that form clusters within membranes, creating ion channels. However, a lack 
of significant antifungal activity in the marinomycins suggests that these new macrolides are not 
membrane active but function through an, as yet, unidentified mechanism [75]. 
Conjugated polyene units also feature in a number of other marine-derived antibacterial natural 
products. Among the earlier anti-MRSA/anti-VRE compounds to be discovered from marine bacteria 
were andrimid and moiramides A to C (Figure 18). These metabolites were produced from cultures of 
a marine isolate of Pseudomonas fluorescens [76], although andrimid had previously been isolated 
from cultures of an Enterobacter symbiont taken from a terrestrial plant hopper, Nilaparvata lugens 
[77,78]. Studies with andrimid showed activity against MRSA (MIC: 2 µg/mL) and VRE (32 µg/mL) 
[76]. Interestingly, the congener with the shorter polyene chain, moiramide B, was apparently more 
potent against both MRSA (0.5 µg/mL) and VRE (4 µg/mL); moiramides A and C were both inactive 
[76]. A screen to discover new marine actinomycete-derived natural products with activity against 
VRE recently identified a Streptomyces sp. (strain 307-9) that produced a culture broth with promising 
activity [79]. The major metabolites responsible for the anti-VRE activity were isolated from 
fermentation extracts and identified as tirandamycins A and B (Figure 19), compounds that had earlier 
been isolated from the culture broth of terrestrial Streptomyces species, S. tirandis and S. flaveolus 
[80,81]. Two new members of this dienoyl tetramic acid family, tirandamycins C and D (respectively 
Figure 19c and d), were recovered from the cultured marine isolate [79]. Assessment of the anti-VRE 
activity for the four tirandamycins revealed that the antibacterial action was strongly dependent on the 
structure of the dioxabicyclo[3.3.1]nonane ring system, with MICs of 2.25, >9, 100 and 110 µM for 
congeners A, D, B and C respectively [79]. 
Figure 18. Andrimid and moiramides A-C. 
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Figure 19. Tirandamycins. 
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Figure 20. Lynamicins A–E and other bisindole alkaloids. 
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Bioassay-guided fractionation of the extracts from the culture broth of another Marinispora species, 
designated NPS12745, provided five halogenated bisindole pyrroles, lynamicins A to E (Figure 20a-e), 
which showed activity against MRSA and VRE [82]. MIC values in the range 1–3 µg/mL and  
2–8 µg/mL were recorded for lynamicins A-D against MRSA and VRE, respectively; lynamicin E was 
somewhat less active (MIC 12 µg/mL and >24 µg/mL against MRSA and VRE) [82]. Bisindole 
alkaloids, especially those belonging to the bisindolylmaleimide group, such as staurosporine [83] and 
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rebeccamycin [84] (Figure 20h/i), have attracted considerable interest because of their well established 
antiproliferative activity in cancer cells. In contrast, the bisindole pyrroles are a far less well 
represented group of compounds, although the core structure is known in metabolites isolated from 
Chromobacterium violaceum and Lycogala epidendrum – lycogalic acid A and the lycogarubins 
(Figure 20f/g) [85–87]. Antibacterial activity for these latter compounds has not previously been 
reported, however, and it is also thought that the indole ring chlorination status may represent a new 
chemotype driven by adaptation to the marine environment [82].  
This review has focused on compounds derived from marine bacteria that exhibit anti-MRSA and 
anti-VRE activity. Marine fungi are also potentially a rich source of bioactive natural products. 
Illustrative of this is the benzophenone antibiotic, pestalone (Figure 21), produced in the mixed 
fermentation of a marine fungus, Pestalotia sp. (strain CNL-365) and an unidentified, antibiotic-
resistant marine bacterium (CNJ-328) [48]. Pestalone exhibited potent activity against MRSA (MIC: 
37 ng/mL) and VRE (MIC: 78 ng/mL). Significantly, pestalone was only produced by the fungus when 
co-cultured with CNJ-328, highlighting the complex dependence of metabolite biosynthesis on culture 
conditions and the potential for enhanced antibiotic production through cross-species  
induction [88–90].  
 
Figure 21. Structure of pestalone. 
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3. Conclusions 
 
Although only approximately 3000 compounds have been characterised from marine bacteria, there 
are already a number of promising compounds demonstrating high levels of activity against MRSA 
and VRE. Compounds derived from actinomycetes are especially prevalent among those identified in 
this review. Terrestrial actinomycetes, taken mainly from soil, have provided a rich source of bioactive 
compounds for more than five decades, yielding in excess of 100,000 bioactive compounds, including 
70% of the antibiotics discovered from natural sources [90]. The paucity of new antibiotic classes to 
emerge since the late 1960s and the challenge now presented by antibiotic-resistant infectious diseases 
underlines the importance of discovering new chemical diversity from natural sources. Further 
investigation may prove marine bacteria to be one such important source of compounds with useful 
clinical applications for recalcitrant and nosocomial infections, such as those caused by MRSA and 
VRE. Adaptation to the marine environment may provide a driving force for chemical diversity 
whereas the competitive environment of some marine niches, as with epiphytic bacteria associated 
with algal surfaces [91], may promote evolutionary development of species capable of producing 
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antibacterial metabolites. Clearly, the recovery of a micro-organism from the ocean does not 
necessarily imply that it is truly ‘marine’, as some organisms may be wash-in components from the 
terrestrial environment. Nevertheless, the marine environment with its novel microflora remains a 
comparatively untapped source of bioactive molecules. Adoption of innovative techniques such as co-
culturing, cross species induction [92] and biofilm development [89,93], to name three examples, may 
further facilitate the discovery of new and useful antibiotics. 
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